Certolizumab pegol in the treatment of spondyloarthritis
Spondyloarthropaties (SpA) are a second common group of inflammatory rheumatic diseases after systemic connective tissue diseases. They are a frequent cause of disability. Tumor necrosis factor α (TNF-α) plays a crucial role in the initiation and continuation of chronic inflammation in SpA patients....
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2014-09-01
|
| Series: | Rheumatology |
| Subjects: | |
| Online Access: | http://www.termedia.pl/Certolizumab-pegol-in-the-treatment-of-spondyloarthritis,18,23337,1,1.html |